Celularity (CELU) EBT Margin (2020 - 2025)
Celularity (CELU) posted quarterly EBT Margin of 593.54% for Q4 2025, up 133858.0% year-over-year from N/an in Q4 2024, and down 35.91% quarter-over-quarter from 436.71% in Q3 2025.
Celularity (CELU) EBT Margin (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported EBT Margin for 6 consecutive years, with 593.54% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBT Margin rose 133858.0% year-over-year to 593.54%; the TTM figure through Dec 2025 stood at 345.44% (down 18802.0% YoY), while the FY2025 annual figure was 345.44%, down 23866.0% from the prior year.
- EBT Margin eased to 593.54% in Q4 2025 per CELU's latest filing, from 436.71% in the prior quarter.
- Across five years, EBT Margin topped out at 1267.03% in Q2 2022 and bottomed at 3065.38% in Q1 2021.
- Historically, EBT Margin has averaged 668.92% across 5 years, with a median of 300.36% in 2024.
- Annual changes were most pronounced in 2022 — EBT Margin surged 328383 bps — and 2023, when it tumbled 289906 bps.
- Celularity's EBT Margin stood at 82.78% in 2021, then jumped by 815 bps to 592.08% in 2022, then tumbled by 87 bps to 78.91% in 2023, then tumbled by 2549 bps to 1932.12% in 2024, then soared by 69 bps to 593.54% in 2025.
- Business Quant data shows CELU's EBT Margin at 593.54% in Q4 2025, 436.71% in Q3 2025, and 427.55% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | -593.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -593.54% |
| Sep 30, 2025 | -436.71% |
| Jun 30, 2025 | -427.55% |
| Mar 31, 2025 | -172.89% |
| Dec 31, 2024 | -1,932.12% |
| Sep 30, 2024 | -173.17% |
| Jun 30, 2024 | -53.57% |
| Mar 31, 2024 | -149.94% |
| Dec 31, 2023 | 78.91% |
| Sep 30, 2023 | -2,479.56% |
| Jun 30, 2023 | -1,632.03% |
| Mar 31, 2023 | -1,626.86% |
| Dec 31, 2022 | 592.08% |
| Sep 30, 2022 | 115.65% |
| Jun 30, 2022 | 1,267.03% |
| Mar 31, 2022 | -1,059.26% |
| Dec 31, 2021 | -82.78% |
| Sep 30, 2021 | 470.14% |
| Jun 30, 2021 | -2,016.80% |
| Mar 31, 2021 | -3,065.38% |